|
1
|
Ellin F, Jerkeman M, Hagberg H and
Relander T: Treatment outcome in T-cell lymphoblastic lymphoma in
adults-a population-based study from the Swedish Lymphoma Registry.
Acta Oncol. 53:927–934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Puig N, Wang L, Seshadri T, al-Farsi K,
Keating A, Crump M and Kuruvilla J: Treatment response and overall
outcome of patients with relapsed and refractory peripheral T-cell
lymphoma compared to diffuse large B-cell lymphoma. Leuk Lymphoma.
54:507–513. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Michot J, Mazeron R, Danu A, Lazarovici J,
Ghez D, Antosikova A, Willekens C, Chamseddine AN, Minard V,
Dartigues P, et al: Concurrent etoposide, steroid, high-dose Ara-C
and platinum chemotherapy with radiation therapy in localised
extranodal natural killer (NK)/T-cell lymphoma, nasal type. Eur J
Cancer. 51:2386–2395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mahadevan D, Unger JM, Spier CM, Persky
DO, Young F, LeBlanc M, Fisher RI and Miller TP: Phase 2 trial of
combined cisplatin, etoposide, gemcitabine, and methylprednisolone
(PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest
oncology group study S0350. Cancer. 119:371–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hill NO: Cis-platinum for cancer. New Engl
J Med. 301:471979. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McKeage MJ: New-generation platinum drugs
in the treatment of cisplatin-resistant cancers. Expert Opin
Investig Drugs. 14:1033–1046. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Last K, Maharaj L, Perry J, Strauss S,
Fitzgibbon J, Lister TA and Joel S: The activity of methylated and
non-methylated selenium species in lymphoma cell lines and primary
tumours. Ann Oncol. 17:773–779. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang C, Wang Z, Ganther H and Lü J:
Distinct effects of methylseleninic acid versus selenite on
apoptosis, cell cycle and protein kinase pathways in du145 human
prostate cancer cells. Mol Cancer Ther. 1:1059–1066.
2002.PubMed/NCBI
|
|
10
|
Wang Z, Jiang C and Lü J: Induction of
caspase-mediated apoptosis and cell-cycle G1 arrest by selenium
metabolite methylselenol. Mol Carcinog. 34:113–120. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Husbeck B, Nonn L, Peehl DM and Knox SJ:
Tumor-selective killing by selenite in patient-matched pairs of
normal and malignant prostate cells. Prostate. 66:218–225. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zeng L, Li Y, Li T, Cao W, Yi Y, Geng W,
Sun Z and Xu H: Selenium-platinum coordination compounds as novel
anticancer drugs: Selectively killing cancer cells via a reactive
oxygen species (ros)-mediated apoptosis route. Chem Asian J.
9:2295–2302. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang K, Chen X, Wuxiao Z, Wang Z, Sun X,
Zeng Z, Li S and Xia ZJ: Long-term outcomes of modified
Berlin-Frankfurt-Münster-90 regimen in adults with T-lymphoblastic
lymphoma: A single-center experience. Leuk Lymphoma. 55:1800–1805.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharma V, Anderson D and Dhawan A: Zinc
oxide nanoparticles induce oxidative DNA damage and ROS-triggered
mitochondria mediated apoptosis in human liver cells (HepG2).
Apoptosis. 17:852–870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Akhtar MJ, Ahamed M, Kumar S, Khan MM,
Ahmad J and Alrokayan SA: Zinc oxide nanoparticles selectively
induce apoptosis in human cancer cells through reactive oxygen
species. Int J Nanomedicine. 7:845–857. 2012.PubMed/NCBI
|
|
16
|
Bonn BR, Krieger D and Burkhardt B: Cell
cycle regulatory molecular profiles of pediatric T-cell
lymphoblastic leukemia and lymphoma. Leuk Lymphoma. 53:557–568.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tait SW and Green DR: Mitochondrial
regulation of cell death. Cold Spring Harb Perspect Biol. 5:pii:
a008706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang WJ, Yu Z and Qiu LG: Research
advances of signal pathway in the pathogenesis of mantle cell
lymphoma. Zhonghua Xue Ye Xue Za Zhi. 34:1073–1075. 2013.(In
Chinese). PubMed/NCBI
|
|
19
|
Gopal PK, Paul M and Paul S: Curcumin
induces caspase mediated apoptosis in JURKAT cells by disrupting
the redox balance. Asian Pac J Cancer Prev. 15:93–100. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sánchez-Martínez C, Gelbert LM, Lallena MJ
and de Dios A: Cyclin dependent kinase (CDK) inhibitors as
anticancer drugs. Bioorg Med Chem Lett. 25:3420–3435. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Levine AJ, Perry ME, Chang A, Silver A,
Dittmer D, Wu M and Welsh D: The 1993 Walter Hubert Lecture: The
role of the p53 tumour-suppressor gene in tumorigenesis. Br J
Cancer. 69:409–416. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Laronga C, Yang HY, Neal C and Lee MH:
Association of the cyclin-dependent kinases and 14-3-3 sigma
negatively regulates cell cycle progression. J Biol Chem.
275:23106–23112. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu C and Bratton SB: Regulation of the
intrinsic apoptosis pathway by reactive oxygen species. Antioxid
Redox signal. 19:546–558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kiraz Y, Adan A, Yandim M Kartal and Baran
Y: Major apoptotic mechanisms and genes involved in apoptosis.
Tumour Biol. 37:8471–8486. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liou G and Storz P: Reactive oxygen
species in cancer. Free Radical Res. 44:479–496. 2010. View Article : Google Scholar
|
|
26
|
Zeng H and Combs GF Jr: Selenium as an
anticancer nutrient: Roles in cell proliferation and tumor cell
invasion. J Nutr Biochem. 19:1–7. 2008. View Article : Google Scholar : PubMed/NCBI
|
